Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) and Green Plains Partners (NASDAQ:GPP – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Risk & Volatility
Cyclo Therapeutics has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, Green Plains Partners has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Valuation and Earnings
This table compares Cyclo Therapeutics and Green Plains Partners’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cyclo Therapeutics||$1.59 million||9.50||-$14.29 million||($1.68)||-1.07|
|Green Plains Partners||$78.45 million||3.84||$40.36 million||$1.70||7.62|
This table compares Cyclo Therapeutics and Green Plains Partners’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Green Plains Partners||52.15%||1,685.26%||34.87%|
This is a breakdown of recent recommendations for Cyclo Therapeutics and Green Plains Partners, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Green Plains Partners||0||1||0||0||2.00|
Cyclo Therapeutics currently has a consensus target price of $16.00, suggesting a potential upside of 793.85%. Green Plains Partners has a consensus target price of $15.00, suggesting a potential upside of 15.83%. Given Cyclo Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cyclo Therapeutics is more favorable than Green Plains Partners.
Insider and Institutional Ownership
4.8% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 17.0% of Green Plains Partners shares are held by institutional investors. 12.0% of Cyclo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Green Plains Partners beats Cyclo Therapeutics on 9 of the 14 factors compared between the two stocks.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
About Green Plains Partners
Green Plains Partners LP provides fuel storage and transportation services in the United States. It acquires, owns, develops, and operates ethanol and fuel storage facilities, terminals, transportation assets, and other related assets and businesses. The company owns or leases 29 ethanol storage facilities and approximately 43 acres of land; and 4 fuel terminals in Alabama, Louisiana, Mississippi, and Oklahoma. It also owns and operates a fleet of 19 trucks and tankers for transportation of ethanol and other products. The company was incorporated in 2015 and is headquartered in Omaha, Nebraska.
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.